Glutathione
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Glutathione is mainly a redox and liver-support tool: it helps replenish intracellular antioxidant capacity, supports Phase II detoxification, and has human evidence for skin-tone evening, oxidative-stress marker reduction, and modest recovery support.
Oral and liposomal use is usually low-toxicity; the safety complexity starts with repeated high-dose IV use, pregnancy or breastfeeding, active cisplatin chemotherapy, and DIY administration.
Glutathione is mainly a redox and liver-support tool: it helps replenish intracellular antioxidant capacity, supports Phase II detoxification, and has human evidence for skin-tone evening, oxidative-stress marker reduction, and modest recovery support. The practical read is bullish but bounded: route and formulation decide most of the outcome.
The main risk is not ordinary oral toxicity; it is using the wrong route in the wrong context. Standard oral products often underperform, repeated high-dose IV beauty use has kidney/nerve/thyroid regulatory warnings, pregnancy and breastfeeding lack pharmacologic-dose safety data, and active cisplatin chemotherapy requires oncology-directed timing because glutathione can theoretically protect tumor cells.
Glutathione is attractive because it targets a real aging and stress bottleneck: intracellular GSH falls with age, NAC rescue is already clinically important in acetaminophen liver toxicity, and several small trials show measurable blood GSH, oxidative-stress, skin, and recovery signals. The value is highest when the route fits the job: NAC for cheap precursor support, liposomal oral for daily redox support, and IV only when rapid high-bioavailability exposure is worth the clinic burden.
Strongly route-dependent. IV users often report fast clarity, energy, and skin changes; liposomal oral users usually report slower, subtler benefits over weeks to months; standard oral users often report nothing. Clinical evidence supports measurable effects, but many claims remain small-trial or marker-based rather than hard outcome proof.
Intro
Glutathione (GSH) is the most abundant intracellular antioxidant in mammalian biology — a tripeptide composed of glutamate, cysteine, and glycine, present at 1–10 millimolar concentrations in most tissues.
Unlike supplemented antioxidants that work systemically, glutathione operates intracellularly, directly neutralizing hydrogen peroxide and lipid peroxides via glutathione peroxidase, detoxifying reactive metabolites through Phase II conjugation, and maintaining the cellular redox environment essential for enzyme function and DNA integrity. Cysteine is the rate-limiting substrate for GSH synthesis, which is why N-acetylcysteine (NAC) is often more effective at raising cellular GSH than oral glutathione itself.
Glutathione levels decline approximately 17% per decade from age 40, with muscle GSH at age 70 estimated at roughly 50% of peak levels. This age-related decline is associated with increased oxidative stress burden, impaired immune function, and reduced detoxification capacity — making GSH replenishment a logical target in healthy aging and longevity protocols. GSH depletion is also associated with chronic disease states, heavy alcohol consumption, acetaminophen toxicity, HIV/AIDS, and Parkinson's disease.
The compound is used clinically in oncology (cisplatin neuropathy and nephrotoxicity prevention), acute liver failure (via NAC, its precursor), and investigationally in Parkinson's disease (IV pilot studies showing 30% functional improvement). In wellness markets, IV glutathione is offered at drip clinics for energy, recovery, and 'glow' effects. In Southeast Asian markets, oral and IV glutathione is a major beauty supplement used for skin tone evenness via tyrosinase inhibition. In bodybuilding communities, it is a standard component of AAS liver support stacks alongside TUDCA and NAC.
The most important practical distinction in glutathione supplementation is route and formulation: IV achieves near-100% bioavailability; liposomal oral achieves meaningful systemic elevation (~40% plasma increase at 500mg/day in RCT); standard unencapsulated oral has minimal bioavailability (broken down by gut GGT before absorption) and produces no noticeable effect for most users.
Observed Effects
The best-documented human effects, by evidence quality:
Skin brightening (Grade B evidence): A 2012 Thai RCT (n=60, 500mg/day, 4 weeks) showed significant melanin index reduction at all six body sites vs placebo. Effect reversed after stopping, confirming the mechanism as active enzyme inhibition rather than permanent structural change. Glutathione inhibits tyrosinase (rate-limiting enzyme in melanin synthesis) and shifts melanin production from dark eumelanin toward lighter phaeomelanin. The skin-brightening effect is real and pharmacological — not placebo.
Blood GSH elevation: Richie et al. 2015 RCT (n=54, 6 months, double-blind): 500mg/day oral raised whole blood GSH by 17%; 1000mg/day by 30–35%. NK cell cytotoxicity increased 400% in the high-dose group — a striking immune signal awaiting replication. Liposomal formulation (Sinha et al. 2018) produced 40% plasma GSH increase at 500mg/day with concurrent reduction in 8-OHdG (oxidative DNA damage marker).
Exercise recovery: A 2015 RCT (n=27, 4 weeks, 100mg/day) reduced post-exercise creatine kinase (muscle damage marker) and subjective fatigue vs placebo in recreational athletes. No effect on maximum strength — this is a recovery, not performance, compound.
Parkinson's disease (preliminary): Sechi et al. 1996 open-label (n=9, IV 600mg 2x/week, 4 months) showed 30% reduction in Parkinson's disability score, with effects persisting 2–4 months after stopping. No RCT confirmation exists. The mechanism — dopaminergic neuron protection from oxidative stress — is sound but requires large-trial confirmation.
Hepatic protection: NAC (GSH precursor) is FDA-approved for acetaminophen-induced acute liver failure — directly confirming the GSH-liver protection mechanism. Direct IV glutathione is used clinically in Italy for liver disease and as cisplatin adjunct in oncology.
Subjective community reports: IV glutathione users describe 'cleaner' feeling, increased energy and clarity, faster skin brightening (weeks vs months for oral), and reduced post-exercise muscle soreness. Oral liposomal users describe gradual improvements in skin quality, less brain fog, and improved recovery. Standard oral users most commonly report no effect.
Field Reports
The standard oral formulation disappointment is the most consistent community experience: users who buy unencapsulated glutathione and take 500mg/day report nothing.
This is the 'expensive urine' characterization — accurate for that form. Users who switch to liposomal or IV almost universally report the formulation change resolves the non-response.
IV glutathione users consistently report among the most pronounced subjective experiences: a 'cleaner' feeling and increased clarity within 24–48 hours of the first session, noticeable skin brightness and evenness developing over 2–4 weeks, reduced post-exercise soreness, and improved energy. The onset is faster than any oral route.
Skin brightening reporters (primarily from Southeast Asian communities) describe gradual skin tone evenness over 2–4 months of consistent oral supplementation (500mg+ liposomal + vitamin C). Most describe 'evening' rather than dramatic lightening — matching the melanin index reduction seen in the clinical RCT. Reversibility is consistently noted: stopping supplementation leads to gradual return to baseline over weeks to months.
AAS users running TUDCA + NAC + glutathione report better maintained liver enzyme values (ALT, AST) during cycles, with less fatigue and better recovery during courses compared to cycles without the support stack. The glutathione's specific contribution is difficult to isolate from the TUDCA and NAC components, but the overall stack has a strong community reputation for hepatoprotection.
The non-responder to liposomal oral is less common but exists — most traced to either incorrect dosing (250mg when 500–1000mg is needed), neglecting vitamin C co-administration, or not allowing sufficient time (minimum 4–8 weeks for oxidative stress effects, 2–3 months for skin changes).
Community Consensus
Glutathione occupies multiple distinct community niches simultaneously. In the AAS and bodybuilding community, it is a standard liver support compound — part of the TUDCA + NAC + GSH trilogy that serious steroid users run throughout oral cycles. In the longevity and biohacking community, it represents the GSH pillar of a multi-system antioxidant approach alongside NMN and CoQ10. In Southeast Asian beauty markets (Philippines, Thailand, Malaysia, Indonesia), oral and IV glutathione is a major commercial category — one of the largest beauty supplement markets in the region — specifically marketed for skin tone evenness. In North American and European wellness markets, IV glutathione drips have become one of the most popular services at IV clinic chains.
The most important community context is the formulation divide: sophisticated users (biohackers, AAS community) understand the bioavailability hierarchy and use liposomal or IV; mainstream supplement consumers buy cheap standard oral and experience no effect, concluding glutathione 'doesn't work' — which is correct for that formulation.
The skin-brightening use case requires careful framing: it is a real pharmacological effect (RCT-confirmed tyrosinase inhibition), but the historical and cultural context of skin lightening in Southeast Asian and African markets involves social pressures around colorism. The article's framing should be mechanistic (tyrosinase inhibition producing melanin index reduction) without aesthetic value judgments.
Regulatory bodies in Southeast Asian countries have issued advisories against IV glutathione specifically for non-clinical beauty use, noting plausible risks from high-dose repeated IV in unmonitored settings. These concerns are legitimate in the context of the beauty market's uncontrolled use patterns.
Risks & Monitoring
At standard oral doses (250–1000mg/day), glutathione is well-tolerated with no serious adverse effects in published trials. The most common complaint at high oral doses is loose stools or GI discomfort.
IV safety at therapeutic doses: IV glutathione up to 1200mg per session is used in clinical settings (oncology, liver disease, Parkinson's research) without major safety signals. Short-term plasma half-life (~2–3 minutes) means rapid tissue distribution with no plasma accumulation.
IV beauty use regulatory concerns: FDA Philippines (2011), and regulatory agencies in Thailand, Malaysia, and Indonesia issued safety advisories specifically against high-dose repeated IV glutathione for skin whitening in uncontrolled settings. Adverse effects cited include kidney damage, peripheral neuropathy, thyroid dysfunction, and Stevens-Johnson syndrome (serious skin reaction). These warnings are based on plausibility and case reports — not controlled trial evidence — and apply primarily to the pattern of frequent high-dose IV use outside medical supervision. The plausibility argument is reasonable: very high exogenous GSH could theoretically disrupt endogenous redox signaling balance.
Drug interaction: IV glutathione may reduce cisplatin chemotherapy efficacy by protecting cancer cells as well as healthy cells. Do not use IV glutathione during active cisplatin chemotherapy without oncologist guidance.
Pregnancy: adequate safety data is lacking — avoid by default. GSH is an endogenous molecule but pharmacological supplementation during pregnancy has not been studied.
No genotoxicity has been documented in published studies.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Most relevant to hepatoprotective use cases rather than routine liposomal oral use. GGT is particularly relevant — it is the enzyme that hydrolyzes oral glutathione (explaining the bioavailability problem) and is an oxidative stress biomarker. Baseline helps quantify liver status before AAS cycles or other hepatotoxic compound use.
8-OHdG (urinary oxidative DNA damage) and 4-HNE (lipid peroxidation marker) directly measure the oxidative load that glutathione addresses. Tracking these before and after supplementation is the best objective way to assess whether GSH supplementation is producing meaningful antioxidant effect. Not widely available at standard labs — hsCRP is a practical surrogate for systemic inflammatory/oxidative burden.
Glutathione supplementation in the Richie 2015 RCT produced significant NK cell cytotoxicity increase (400%). For users targeting immune support, baseline immune cell counts (NK cells, lymphocytes) provide a comparator, though NK cytotoxicity testing requires specialized assays not available at standard labs.
Relevant for frequent IV users, high-dose users, or people with kidney risk factors, given the regulatory concerns about kidney effects from high-dose repeated IV glutathione. Routine oral/liposomal use does not require this as a safety gate.
Avoid With
Do not combine Glutathione with the following. Sorted highest-severity first.
Why:Glutathione may protect cancer cells as well as healthy cells from cisplatin's oxidative damage mechanism, potentially reducing chemotherapy efficacy.
What to do:Do not use during active cisplatin treatment without oncologist guidance. Paradoxically, glutathione is also used to PREVENT cisplatin side effects — the timing and dose matter critically. This is a medical decision, not a DIY stacking call.
Why:Exogenously pushing very high GSH levels may theoretically disrupt endogenous redox signaling homeostasis; regulatory bodies have cited kidney, nerve, and thyroid concerns from this pattern.
What to do:Not a concern at therapeutic doses or standard IV wellness clinic use. Applies specifically to the pattern of daily high-dose (1200mg+) IV administration outside clinical monitoring.
Protocols By Goal
Liver support during AAS or hepatotoxic compound use: TUDCA 250–500mg/day + NAC 600–1200mg/day + glutathione (oral or IV).
Start at cycle initiation, continue 4 weeks post-cycle. If oral, use liposomal form. The TUDCA + NAC + GSH trinity is the standard AAS liver support stack in community use, with each compound addressing a different hepatoprotective mechanism.
Skin brightening: liposomal glutathione 500–1000mg/day + Vitamin C 500–1000mg/day. Take morning with food. Minimum 3-month course before assessing visible effect. Add alpha-lipoic acid 100–200mg/day to extend effect via GSH recycling. Expect gradual evening of skin tone rather than dramatic lightening; effect reverses after stopping.
Longevity / oxidative stress reduction: liposomal glutathione 250–500mg/day + NMN 250–500mg/day + CoQ10 100–200mg/day + alpha-lipoic acid 100–300mg/day. Continuous daily use. This multi-pathway stack addresses GSH system, NAD+ dependent antioxidant enzymes, mitochondrial electron transport, and GSH recycling simultaneously.
Exercise recovery: 100–500mg oral glutathione (liposomal preferred) taken post-workout. May reduce post-exercise muscle damage markers (CK) and subjective soreness. Combine with vitamin C and magnesium for broad recovery support.
IV wellness protocol: 600mg IV glutathione 1–4 times per month at a clinical or wellness setting. Assess response after 4 sessions. Some users report noticeable energy and skin improvements within the first 1–2 sessions; others require 4–6 before noticing change.
Dosing Details
Route determines everything in glutathione supplementation.
Standard oral (unencapsulated reduced glutathione): 250–1000mg/day. Largely ineffective for most users due to intestinal hydrolysis by gamma-glutamyl transpeptidase. May produce minor blood GSH increases with sustained high dosing (Richie et al. showed 17% increase at 500mg/day over 6 months) but most users notice no subjective effect. Not the recommended oral form.
Liposomal oral (encapsulated to protect from gut hydrolysis): 500–1000mg/day. The preferred oral route. Produces ~40% plasma GSH increase at 500mg/day (Sinha et al. 2018 RCT). Morning on empty stomach is most commonly recommended. Key brands with documented formulations: Readisorb, Core Med Science liposomal glutathione.
Sublingual reduced glutathione: 100–300mg held under tongue 2–5 minutes before swallowing. Partially bypasses gut hydrolysis via buccal absorption. Less studied than liposomal but preferred by some users.
IV (clinical or wellness clinic): 600–1200mg per session. Most common clinic dose is 600mg in saline, administered over 15–30 minutes. Frequency: daily (medical contexts) to 1–4x/month (wellness maintenance). Near-100% bioavailability. Onset of effects within 24–48 hours. Route of choice for highest efficacy.
Cofactor co-administration: Vitamin C 500–1000mg potentiates GSH (regenerates GSSG back to GSH, independently inhibits tyrosinase for skin effects). Alpha-lipoic acid 100–300mg recycles GSH and extends the antioxidant effect. Both are standard additions in community protocols.
Skin brightening: oral glutathione (liposomal preferred) 500–1000mg/day + Vitamin C 500–1000mg/day. Minimum 2–3 months for visible skin changes. Effects reverse after stopping — continuous use required to maintain results.
Stacks & Alternatives
AAS / oral steroid liver support trinity. TUDCA is bile-acid hepatoprotective; NAC is GSH precursor + direct antioxidant; glutathione provides direct GSH supplementation + Phase II detox support. The three mechanisms are complementary, not redundant. Standard AAS community protocol.
Redox synergy stack. Vitamin C regenerates oxidized GSSG back to active GSH and independently inhibits tyrosinase; alpha-lipoic acid recycles GSH and chelates transition metals. Together these compounds extend and amplify glutathione's antioxidant effect. Core of the skin brightening protocol and general oxidative stress stack.
Longevity / mitochondrial support stack. Glutathione addresses cytoplasmic redox; NMN raises NAD+ for sirtuin-mediated antioxidant response; CoQ10 protects mitochondrial membranes and supports electron transport chain function. Each targets a different cellular compartment and redox system.
Alternatives
Stack Cost
Low stack tax for oral/liposomal redox support, rising to moderate when IV logistics, oncology timing, pregnancy/breastfeeding, or repeated high-dose beauty use enter the picture.
The article's hard conflict is cisplatin chemotherapy because glutathione may protect cancer cells as well as healthy cells. Outside oncology timing, interaction burden is limited.
IV use has near-100% bioavailability and fast onset, but requires licensed clinical or wellness providers, sterile administration, and avoidance of unmonitored high-dose beauty-drip patterns.
Routine liposomal oral use does not need a hormone-style lab panel. Liver or renal labs become useful when glutathione is supporting hepatotoxic compounds, frequent IV use, or a known medical condition.
The article describes standard oral as poor value, liposomal oral as acceptable, and IV drips as highest efficacy but costly. Choosing the wrong formulation wastes stack budget.
The article says pregnancy and breastfeeding data are inadequate despite glutathione being endogenous, so pharmacologic supplementation should be avoided by default in those contexts.
- ·For most users, count liposomal glutathione as an antioxidant/redox support lane, not as a hormone, stimulant, GH/IGF, or appetite lane.
- ·Do not use IV glutathione during active cisplatin chemotherapy without oncologist-directed timing.
- ·If the goal is simply raising cellular glutathione on a budget, consider NAC first because the article identifies cysteine availability as rate-limiting.
- ·Avoid spending capacity on standard unencapsulated oral glutathione when efficacy matters; the article frames it as the main formulation trap.
- ·Escalate tax from low to moderate when moving from oral liposomal use to repeated IV sessions.
- ·Formulation selection: liposomal, sublingual, or IV rather than ordinary unencapsulated oral when efficacy is the goal.
- ·Vitamin C co-administration to regenerate GSSG back to active GSH and support skin-brightening protocols.
- ·Optional alpha-lipoic acid when extending redox cycling is part of the protocol.
- ·Licensed IV provider and renal/liver baseline checks for frequent IV use.
- ·Oncology review if any platinum chemotherapy is involved.
The article describes oral and liposomal use as non-hormonal and generally well tolerated, and the main beginner failure mode is wasting money on the wrong formulation rather than creating suppression or withdrawal.
- ·Self-administering IV product
- ·Using frequent high-dose IV for skin whitening without medical supervision
- ·Currently receiving cisplatin or other active cancer therapy
The article describes glutathione effects such as skin brightening as reversible after stopping and does not identify withdrawal, endocrine suppression, or taper requirements.
- ·Skin-brightening effects gradually reverse after discontinuation.
- ·Subjective IV effects such as clarity or energy may fade quickly.
- ·If used as support for another hepatotoxic compound, the other compound determines the real off-ramp risk.
Switch to liposomal, sublingual, IV, or NAC-based precursor support depending on goal and budget.
Do not self-direct this combination; the article treats timing and dose as a medical decision because tumor protection is the concern.
Use licensed providers, stay within conservative dosing, and avoid repeated high-dose unmonitored protocols flagged by Southeast Asian regulators.
The article identifies this as the primary drug-interaction concern because glutathione may reduce chemotherapy efficacy if timed incorrectly.
The article notes inadequate pharmacologic-dose safety data despite endogenous GSH biology.
Regulatory warnings cited in the article focus on kidney, nerve, thyroid, and severe skin-reaction concerns from uncontrolled beauty-drip patterns.
The article's main efficacy trap is intestinal GGT breakdown of ordinary oral GSH before intact absorption.
Practical Setup
The most important practical decision is formulation: standard oral glutathione is largely wasted money for most users.
If using oral route, liposomal is the minimum viable formulation. If budget is a concern, NAC at 600–1200mg/day is a substantially cheaper alternative that raises cellular glutathione via the cysteine-precursor pathway — often more effectively than oral glutathione itself.
Vitamin C co-administration (500–1000mg) is recommended regardless of route — it regenerates GSSG back to active GSH and extends the antioxidant effect at minimal cost. Alpha-lipoic acid (100–300mg) further extends effects via GSH recycling.
For IV users: use licensed clinical or wellness clinic providers. Self-administered IV is not recommended and illegal in many jurisdictions. The FDA Philippines and other Asian regulatory concerns are specifically about unmonitored high-dose beauty use, not clinical use. IV at wellness clinics (600–1200mg in saline, 15–30 minutes) has a good safety record.
The cisplatin interaction is the primary drug interaction concern. Any cancer patient considering glutathione supplementation during chemotherapy must discuss with their oncologist — the timing of glutathione relative to cisplatin administration is a medical decision.
For pregnant or breastfeeding women: insufficient data — avoid supplementation by default. Glutathione is an endogenous molecule but pharmacological doses during pregnancy have not been studied.
Storage: oral supplements — cool, dry, dark location; away from heat and humidity. Reduced glutathione oxidizes to GSSG on prolonged air/light exposure, rendering it inactive. Powder formulations are particularly vulnerable; capsules in sealed containers are preferred. IV vials should be refrigerated and used promptly after opening.
Mechanism Deep Dive
Glutathione (GSH) is the cell's primary reducing agent and antioxidant. Its three-amino-acid structure (γ-glutamyl-cysteinyl-glycine) includes a free sulfhydryl group on cysteine that is the reactive site — it donates electrons to neutralize reactive oxygen species (ROS) and free radicals, becoming oxidized to glutathione disulfide (GSSG). GSSG is then regenerated to active GSH by glutathione reductase using NADPH as the electron donor — completing the cycle.
Glutathione peroxidase (GPx) uses two molecules of GSH to reduce hydrogen peroxide to water and GSSG. This is the primary mechanism by which glutathione neutralizes oxidative damage. GPx also reduces organic hydroperoxides (lipid peroxides), protecting membrane integrity.
Phase II detoxification: in the liver, GSH S-transferases conjugate reactive metabolites (from Phase I CYP450 oxidation) with glutathione, making them water-soluble for renal excretion. This conjugation is essential for elimination of drugs, environmental toxins, heavy metals (mercury, lead, arsenic), and endogenous metabolites. This mechanism explains glutathione's hepatoprotective role.
Skin brightening mechanism: GSH inhibits tyrosinase (the rate-limiting enzyme in melanin synthesis via the DOPA → dopaquinone pathway) both directly (competitive inhibition) and indirectly (by reducing dopaquinone back to DOPA before polymerization). GSH also shifts melanogenesis from dark eumelanin synthesis toward lighter phaeomelanin production. The net effect is reduced melanin deposition in melanocytes and the surrounding keratinocytes.
Oral bioavailability limitation: intestinal epithelial cells express gamma-glutamyl transpeptidase (GGT) on their luminal surface. GGT cleaves the gamma-glutamyl bond in glutathione, breaking the tripeptide into its constituent amino acids before absorption. Cysteine (the limiting amino acid) is then absorbed but rapidly metabolized. This is why standard oral glutathione shows minimal plasma elevation — it arrives at tissues not as GSH but as its component parts. Liposomal encapsulation physically protects the tripeptide from GGT during transit, enabling absorption of the intact molecule.
Cysteine as rate-limiting substrate: GSH synthesis is catalyzed by two enzymes: glutamate-cysteine ligase (GCL) and glutathione synthetase. GCL catalyzes the first and rate-limiting step, combining glutamate and cysteine. Cysteine availability determines the rate of GSH synthesis. This is why NAC (acetylcysteine) — which delivers cysteine after deacetylation in vivo — is often more effective at raising cellular GSH than oral glutathione itself.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
500mg/day oral glutathione raised whole blood GSH by 17%; 1000mg/day by 30–35% vs placebo over 6 months
Richie et al., Eur J Nutr 2015. Double-blind RCT. Primary human oral GSH efficacy trial. Tissue GSH not directly measured — blood proxy. NK cell activity increase (400% at high dose) requires replication.
Oral glutathione 500mg/day for 4 weeks significantly reduced melanin index at all six body sites vs placebo
Arjinpathana & Asawanonda, J Dermatolog Treat 2012. RCT. Melanin index reversed after stopping — confirms tyrosinase inhibition as mechanism. Effect grade B per Examine.com.
Liposomal glutathione 500mg/day produced ~40% plasma GSH increase and reduced 8-OHdG vs unencapsulated oral at same dose
Sinha et al., Eur J Nutr 2018. 4-week RCT. Definitive head-to-head comparison establishing liposomal superiority. 8-OHdG (oxidative DNA damage) reduction confirms functional effect.
IV glutathione 600mg twice weekly for 4 months produced 30% reduction in Parkinson's disability score, persisting 2–4 months after stopping
Sechi et al., Prog Neuropsychopharmacol Biol Psychiatry 1996. Open-label, no control. Small n limits conclusions. The post-cessation persistence (2–4 months) suggests disease-modifying rather than purely symptomatic effect. Requires large RCT confirmation.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.